lianprocaine disodium

Lianprocaine disodium is a novel intravenous anesthetic agent currently under clinical investigation for the induction of general anesthesia. Developed by researchers at the Tianjin Cancer Hospital Airport Hospital, it is a derivative of the local anesthetic procaine. Unlike traditional local anesthetics, lianprocaine is designed for systemic administration to achieve sedation and hypnosis suitable for anesthesia induction, comparable to propofol. A distinguishing feature of lianprocaine is its potential immunomodulatory effect; it is being studied for its ability to preserve or enhance immune function (such as natural killer cell activity) in patients undergoing neoadjuvant chemotherapy for breast cancer, potentially offering oncological benefits over standard agents like propofol by mitigating surgical stress-induced immunosuppression.

Other names

lianprocainelianprocaine disodium